Hurley Capital LLC Invests $68,000 in Exelixis, Inc. (NASDAQ:EXEL)

Hurley Capital LLC bought a new position in shares of Exelixis, Inc. (NASDAQ:EXEL) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund bought 2,000 shares of the biotechnology company’s stock, valued at approximately $68,000.

Other large investors have also recently bought and sold shares of the company. USA Financial Formulas bought a new position in shares of Exelixis during the 4th quarter worth about $32,000. Principal Securities Inc. increased its stake in Exelixis by 62.8% during the fourth quarter. Principal Securities Inc. now owns 967 shares of the biotechnology company’s stock valued at $32,000 after acquiring an additional 373 shares during the period. Kestra Investment Management LLC acquired a new position in Exelixis in the 4th quarter valued at approximately $39,000. UMB Bank n.a. lifted its position in shares of Exelixis by 68.4% in the 4th quarter. UMB Bank n.a. now owns 1,361 shares of the biotechnology company’s stock worth $45,000 after acquiring an additional 553 shares during the period. Finally, Crowley Wealth Management Inc. acquired a new stake in shares of Exelixis during the 4th quarter worth approximately $50,000. 85.27% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

EXEL has been the subject of several research reports. Stifel Nicolaus raised their target price on Exelixis from $30.00 to $36.00 and gave the stock a “hold” rating in a research report on Wednesday, February 12th. Brookline Capital Management initiated coverage on Exelixis in a report on Monday, December 23rd. They issued a “buy” rating on the stock. Guggenheim reissued a “buy” rating and set a $42.00 price objective on shares of Exelixis in a report on Wednesday, February 12th. Royal Bank of Canada lifted their target price on Exelixis from $38.00 to $40.00 and gave the company an “outperform” rating in a research note on Thursday, March 13th. Finally, JMP Securities reiterated a “market outperform” rating and set a $41.00 price target on shares of Exelixis in a research report on Thursday, January 23rd. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Exelixis currently has a consensus rating of “Moderate Buy” and an average target price of $37.59.

Exelixis Stock Down 5.8 %

Shares of EXEL stock opened at $34.57 on Friday. The firm has a fifty day moving average of $35.90 and a 200-day moving average of $33.60. Exelixis, Inc. has a 12-month low of $20.14 and a 12-month high of $40.02. The company has a market capitalization of $9.68 billion, a price-to-earnings ratio of 19.53, a P/E/G ratio of 1.13 and a beta of 0.57.

Exelixis (NASDAQ:EXEL) last posted its quarterly earnings data on Tuesday, February 11th. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.51 by ($0.03). Exelixis had a net margin of 24.04% and a return on equity of 23.52%. On average, equities analysts expect that Exelixis, Inc. will post 2.04 EPS for the current year.

Insider Buying and Selling at Exelixis

In other news, EVP Patrick J. Haley sold 10,000 shares of the company’s stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $38.80, for a total value of $388,000.00. Following the sale, the executive vice president now directly owns 341,028 shares of the company’s stock, valued at approximately $13,231,886.40. This represents a 2.85 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Bob Oliver sold 18,647 shares of Exelixis stock in a transaction that occurred on Tuesday, February 25th. The stock was sold at an average price of $37.25, for a total value of $694,600.75. Following the transaction, the director now owns 33,514 shares of the company’s stock, valued at $1,248,396.50. This represents a 35.75 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 140,343 shares of company stock worth $5,177,234 over the last ninety days. 2.85% of the stock is currently owned by corporate insiders.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.